ICIs targeting CTLA4 effectively enhance immunity, activate T cells, induce immunological memory, as well as upregulate the T cell response to tumor-associated neoantigens to kill cancer cells and attack Treg cells in tumors (Seidel et al., 2018). Here, CTLA4 is linked to cancer.